Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Physiomics ( (GB:PYC) ).
Physiomics plc has announced a new contract with Numab Therapeutics AG, involving the use of Pharmacokinetic-Pharmacodynamic modelling to enhance a key asset in Numab’s pipeline. This collaboration underscores Physiomics’ expertise in modelling and simulation to expedite therapeutic development, reinforcing its position as a valuable partner in the drug development process.
More about Physiomics
Physiomics plc is a company specializing in mathematical modelling, data science, and biostatistics, supporting the development of new therapeutics and personalized medicine solutions. It helps biotech and pharma companies streamline drug development using computational tools and proprietary technology, such as Virtual Tumour, to optimize research design across various stages. Its clients include notable names like Merck KGaA, Astellas, and Numab Therapeutics.
YTD Price Performance: -56.25%
Average Trading Volume: 1,530,137
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.42M
See more data about PYC stock on TipRanks’ Stock Analysis page.
